Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kogenate continuous infusion in hemophilia A surgery
NCT00606060Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant human coagulation factor VIII in hemophilia A, sponsored by Bayer. Primary endpoint: Efficacy of continuous infusion of recombinant Factor VIII - sucrose-formulated (rFVIII-FS) at 28 days. Started Jul 2004; status: completed.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00606060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00606060.